Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04964934
Title Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca

Her2-receptor negative breast cancer


Abemaciclib + Camizestrant

Letrozole + Palbociclib

Abemaciclib + Letrozole

Anastrozole + Palbociclib

Abemaciclib + Anastrozole

Camizestrant + Palbociclib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | AUT

No variant requirements are available.